{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T17:19:34Z","timestamp":1648660774382},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.2169\/internalmedicine.0583-17","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T17:26:49Z","timestamp":1520530009000},"page":"2179-2183","source":"Crossref","is-referenced-by-count":2,"title":["Large Bowel Progressive Stricture after Infliximab Therapy for Crohn's Disease"],"prefix":"10.2169","volume":"57","author":[{"given":"Katsunori","family":"Matsueda","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Fukuyama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Toyokawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Fukuyama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Fukuyama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Fukuyama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jouichiro","family":"Horii","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Hospital Organization Fukuyama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Rutgeerts P, D&apos;Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn&apos;s disease. Gastroenterology 117: 761-769, 1999.","DOI":"10.1016\/S0016-5085(99)70332-X"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn&apos;s disease: the ACCENT I randomised trial. Lancet (London, England) 359: 1541-1549, 2002.","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 5: 119-133, 1999.","DOI":"10.1097\/00054725-199905000-00008"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43: 2383-2390, 2000.","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Baeten D, Kruithof E, Van den, Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 62: 829-834, 2003.","DOI":"10.1136\/ard.62.9.829"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. First MR, Peddi VR. Malignancies complicating organ transplantation. Transplant proc 30: 2768-2770, 1998.","DOI":"10.1016\/S0041-1345(98)00805-7"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Melichar B, Bures J, Dedic K. Anorectal carcinoma after infliximab therapy in Crohn&apos;s disease: report of a case. Dis Colon Rectum 49: 1228-1233, 2006.","DOI":"10.1007\/s10350-006-0647-6"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn&apos;s disease: the Mayo clinic experience in 500 patients. Gastroenterology 126: 19-31, 2004.","DOI":"10.1053\/j.gastro.2003.10.047"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46: 3151-3158, 2002.","DOI":"10.1002\/art.10679"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn&apos;s disease: TREAT registry. Clin Gastroenterol Hepatol 4: 621-630, 2006.","DOI":"10.1016\/j.cgh.2006.03.002"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Baxevanis CN, Voutsas IF, Tsitsilonis OE, Tsiatas ML, Gritzapis AD, Papamichail M. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice. Eur J Immunol 30: 1957-1966, 2000.","DOI":"10.1002\/1521-4141(200007)30:7<1957::AID-IMMU1957>3.0.CO;2-7"},{"key":"12","unstructured":"12. Dossett LA, White LM, Welch DC, et al. Small bowel adenocarcinoma complicating Crohn&apos;s disease: case series and review of the literature. Am Surg 73: 1181-1187, 2007."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/15\/57_0583-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T10:28:51Z","timestamp":1570876131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/15\/57_0583-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":12,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0583-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}